At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Hypericin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
In Brief
A Phase 2 clinical trial evaluating Hypericin and Mechlorethamine Topical Gel for Cutaneous T-Cell Lymphoma/Mycosis Fungoides. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The objective of this clinical study is to compare the safety and effectiveness of Valchlor versus HyBryte following 12 weeks of treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
First PostedNov 2023
Enrollment StartDec 2023
Primary CompletionMay 2024
Study CompletionJun 2024
TodayJul 2026
First PostedNov 28, 2023
Enrollment StartDec 5, 2023
Primary CompletionMay 31, 2024
Study CompletionJun 27, 2024
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 2.6 years ago
Interventions
Hypericindrug
HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment.
Mechlorethamine Topical Geldrug
Valchlor is an FDA-approved drug for the treatment of CTCL.